• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Are opinions changing on changing therapies in MS?

October 22, 2019  

New developments in secondary-progressive MS – ECTRIMS 2019

October 10, 2019  

Report on higher-efficacy therapies in MS – ECTRIMS 2019

October 2, 2019  

ECTRIMS 2019 SLIDE DECK

September 26, 2019  

ECTRIMS 2019 DAILY REPORT – SATURDAY EDITION

September 14, 2019  

ECTRIMS 2019 DAILY REPORT – FRIDAY EDITION

September 13, 2019  

ECTRIMS 2019 DAILY REPORT – THURSDAY EDITION

September 12, 2019  

Progressive MS trials – design and interpretation

September 4, 2019  

Ponesimod – phase III results in MS

July 31, 2019  

¿Quién es más inerte?

July 24, 2019  
Previous
21
22
23
24
25
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions